Monthly pill could revolutionize HIV prevention
NCT ID NCT06045507
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental oral drug called MK-8527, taken once a month, to see if it is safe and how it works in the body for HIV prevention. 352 HIV-negative adults at low risk for infection participated. The main goals were to check for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-8527 (an experimental oral drug taken once a month)
What this could lead to
If successful, this could lead to a convenient once-monthly pill to prevent HIV infection, offering an alternative to daily PrEP.
What could go wrong
This is an early-phase trial focused on safety and drug levels, not yet on effectiveness. The drug may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albuquerque Clinical Trials, Inc. ( Site 0044)
Albuquerque, New Mexico, 87102, United States
-
Bridge HIV- San Francisco Department of Public Health ( Site 0042)
San Francisco, California, 94102, United States
-
Community Medical Care Center ( Site 0056)
Immokalee, Florida, 34142, United States
-
Desmond Tutu Health Foundation ( Site 0021)
Cape Town, Western Cape, 7925, South Africa
-
Fenway Health ( Site 0043)
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0057)
Seattle, Washington, 98104, United States
-
Hadassah Medical Center ( Site 0002)
Jerusalem, 9112001, Israel
-
Helen Joseph Hospital ( Site 0024)
Johannesburg, Gauteng, 2092, South Africa
-
Josha Research ( Site 0023)
Bloemfontein, Free State, 9301, South Africa
-
Prism Health North Texas, Oak Cliff Health Center ( Site 0045)
Dallas, Texas, 75208, United States
-
Qhakaza Mbokodo Research Clinic ( Site 0026)
Ladysmith, KwaZulu-Natal, 3370, South Africa
-
Rambam Health Care Campus ( Site 0003)
Haifa, 3109601, Israel
-
Sheba Medical Center ( Site 0001)
Ramat Gan, 5265601, Israel
-
University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041)
Pittsburgh, Pennsylvania, 15213, United States
-
Velocity Clinical Research Rockville ( Site 0048)
Rockville, Maryland, 20854, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0052)
Hallandale, Florida, 33009, United States
-
Velocity Clinical Research, North Hollywood ( Site 0054)
North Hollywood, California, 91606, United States
-
Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027)
Johannesburg, Gauteng, 2000, South Africa